19
Views
64
CrossRef citations to date
0
Altmetric
Signal Transduction

The LIM Protein Ajuba Influences Interleukin-1-Induced NF-κB Activation by Affecting the Assembly and Activity of the Protein Kinase Cζ/p62/TRAF6 Signaling Complex

&
Pages 4010-4022 | Received 20 Sep 2004, Accepted 22 Feb 2005, Published online: 27 Mar 2023
 

Abstract

The Zyxin/Ajuba family of cytosolic LIM domain-containing proteins has the potential to shuttle from sites of cell adhesion into the nucleus and thus can be candidate transducers of environmental signals. To understand Ajuba's role in signal transduction pathways, we performed a yeast two-hybrid screen with the LIM domain region of Ajuba. We identified the atypical protein kinase C (aPKC) scaffold protein p62 as an Ajuba binding partner. A prominent function of p62 is the regulation of NF-κB activation in response to interleukin-1 (IL-1) and tumor necrosis factor signaling through the formation of an aPKC/p62/TRAF6 multiprotein signaling complex. In addition to p62, we found that Ajuba also interacted with tumor necrosis factor receptor-associated factor 6 (TRAF6) and PKCζ. Ajuba recruits TRAF6 to p62 and in vitro activates PKCζ activity and is a substrate of PKCζ. Ajuba null mouse embryonic fibroblasts (MEFs) and lungs were defective in NF-κB activation following IL-1 stimulation, and in lung IKK activity was inhibited. Overexpression of Ajuba in primary MEFs enhances NF-κB activity following IL-1 stimulation. We propose that Ajuba is a new cytoso lic component of the IL-1 signaling pathway modulating IL-1-induced NF-κB activation by influencing the assembly and activity of the aPKC/p62/TRAF6 multiprotein signaling complex.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mcb.asm.org/.

ACKNOWLEDGMENTS

This work was supported by grant CA75315 from the NIH and a grant from the Washington University/Pfizer biomedical research program to G.D.L.

We thank Robert Arch, P. Ross, and S. Teitelbaum for comments and suggestions, Mary Beckerle for Zyxin null mice, J. Moscat and T. Diaz-Meco for plasmids and p62 antiserum, and J. Weber for nucleophosmin antiserum.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.